Therapeutic use of antibodies against ENPP3

Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nuclei...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Zhejiang Shimai Pharmaceutical Co., Ltd
Format:	Patent
Sprache:	eng
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	Zhejiang Shimai Pharmaceutical Co., Ltd
description	Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.
format	Patent
fullrecord	<record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_11766479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11766479</sourcerecordid><originalsourceid>FETCH-uspatents_grants_117664793</originalsourceid><addsrcrecordid>eNrjZNAOyUgtSixILS3JTFYoLU5VyE9TSMwryUzKT8lMLVZITE_MzCsuUXD1Cwgw5mFgTUvMKU7lhdLcDApuriHOHrqlxQWJJal5JcXx6UWJIMrQ0NzMzMTc0pgIJQAHMCnB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Therapeutic use of antibodies against ENPP3</title><source>USPTO Issued Patents</source><creator>Zhejiang Shimai Pharmaceutical Co., Ltd</creator><creatorcontrib>Zhejiang Shimai Pharmaceutical Co., Ltd</creatorcontrib><description>Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.</description><language>eng</language><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11766479$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64012</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11766479$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Zhejiang Shimai Pharmaceutical Co., Ltd</creatorcontrib><title>Therapeutic use of antibodies against ENPP3</title><description>Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZNAOyUgtSixILS3JTFYoLU5VyE9TSMwryUzKT8lMLVZITE_MzCsuUXD1Cwgw5mFgTUvMKU7lhdLcDApuriHOHrqlxQWJJal5JcXx6UWJIMrQ0NzMzMTc0pgIJQAHMCnB</recordid><startdate>20230926</startdate><enddate>20230926</enddate><creator>Zhejiang Shimai Pharmaceutical Co., Ltd</creator><scope>EFH</scope></search><sort><creationdate>20230926</creationdate><title>Therapeutic use of antibodies against ENPP3</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_117664793</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Zhejiang Shimai Pharmaceutical Co., Ltd</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><aucorp>Zhejiang Shimai Pharmaceutical Co., Ltd</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Therapeutic use of antibodies against ENPP3</title><date>2023-09-26</date><risdate>2023</risdate><abstract>Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_uspatents_grants_11766479
source	USPTO Issued Patents
title	Therapeutic use of antibodies against ENPP3
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A05%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.aucorp=Zhejiang%20Shimai%20Pharmaceutical%20Co.,%20Ltd&rft.date=2023-09-26&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E11766479%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true